Actively Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
38
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Xiamen University
Lead Sponsor
T
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).
CONDITIONS
Official Title
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years, any gender
- Newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL) confirmed by pathology
- At least one measurable or evaluable lesion by PET/CT, CT, or MRI based on specified size criteria
- ECOG performance status of 0 to 2
- Left ventricular ejection fraction less than 45%
- HBV-positive patients can participate only if HBV-DNA test is negative
- Normal major organ function including liver and renal function within defined limits
- Blood counts meeting minimum levels for neutrophils, platelets, and hemoglobin
- Life expectancy of at least 6 months
- Signed informed consent form
You will not qualify if you...
- Primary or secondary central nervous system DLBCL
- HIV-positive or active HCV infection
- Severe cardiovascular diseases including uncontrolled hypertension, arrhythmias, symptomatic angina, or advanced heart failure
- Severe chronic obstructive pulmonary disease with hypoxemia
- Active bacterial, fungal, or viral infections not controlled by treatment
- Other malignancies within the past 3 years or concurrent cancers except certain early-stage or cured cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
B
Bing Xu, PhD
CONTACT
Z
Zhifeng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here